Congratulations to our partner, @AllogeneTx, on receiving Fast Track designation for ALLO-605, the first TurboCAR™ T cell therapy candidate, that targets #BCMA for the treatment of relapsed or refractory multiple #myeloma.
#MultipleMyeloma #MM #celltherapy

Allogene Therapeutics@AllogeneTx

Today we announced the @US_FDA granted Fast Track designation to our first TurboCAR™ candidate which targets BCMA for the treatment of relapsed or refractory multiple #myeloma.

JOIN US TODAY -- The race is on to provide adoptive #celltherapy to #oncology patients. Learn how utilizing a GMP-compatible manufacturing workflow with nS/MARt DNA Vector Platform and our Flow #Electroporation can help. Register before it’s too late: http://ow.ly/Rn5450Ff44a

1 WEEK LEFT TO REGISTER! The race is on to provide adoptive #celltherapy to #oncology patients. Join us to learn how utilizing a GMP-compatible manufacturing workflow with nS/MARt DNA Vector Platform and our Flow #Electroporation can help. Sign up today: http://ow.ly/SzyF50Ff3QJ

The race is on to provide adoptive #celltherapy to #oncology patients. Join our webinar to learn how utilizing a GMP-compatible manufacturing workflow with the nS/MARt DNA Vector Platform and our Flow #Electroporation can help. Register today: http://ow.ly/k1wt50FaU0x

Load More...

Congratulations to our partner, @CaribouBio, on dosing the first patient in their phase 1 #clinicaltrial to evaluate the company’s lead candidate, CB-010, in patients with relapsed or refractory B cell non-Hodgkin #lymphoma: https://t.co/8RkhOwpW6K.
#celltherapy #CRISPR https://t.co/EseagSAki9
MaxCyte_info photo
Caribou Biosciences @CaribouBio
Thrilled to announce that the first patient has been dosed in our phase 1 clinical trial to evaluate a differentiated #CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy for patients with relapsed or refractory B cell non-Hodgkin lymphoma. Learn more: https://t.co/Gsdschu9Xv https://t.co/ONeYOz98gy

Congratulations to our partner, @AllogeneTx, on receiving Fast Track designation for ALLO-605, the first TurboCAR™ T cell therapy candidate, that targets #BCMA for the treatment of relapsed or refractory multiple #myeloma.
#MultipleMyeloma #MM #celltherapy https://t.co/a2k0WJ1KG4

JOIN US TODAY -- The race is on to provide adoptive #celltherapy to #oncology patients. Learn how utilizing a GMP-compatible manufacturing workflow with nS/MARt DNA Vector Platform and our Flow #Electroporation can help. Register before it’s too late: https://t.co/RXUlV6ogZc https://t.co/eMXCXHNUg3 MaxCyte_info photo

1 WEEK LEFT TO REGISTER! The race is on to provide adoptive #celltherapy to #oncology patients. Join us to learn how utilizing a GMP-compatible manufacturing workflow with nS/MARt DNA Vector Platform and our Flow #Electroporation can help. Sign up today: https://t.co/t12MQ42S7B https://t.co/ZDzX7gr7PE MaxCyte_info photo